UK unveils plans to make antibiotic R&D more attractive for the pharmaceutical industry Pharmaceutical companies could be paid a lump sum to reward them for developing successful new antibiotics under proposals designed to ‘de-link’ the profitability of a new drug from its sales volume and make research and development a viable proposition.…
Impaired kidney function may not justify avoidance of nitrofurantoin Advice not to use nitrofurantoin to treat patients with urinary tract infections who have impaired kidney function may be unfounded, research suggests.…
Anthelmintic drugs niclosamide and oxyclozanide can target staphylococcal infections Niclosamide was bacteriostatic whereas oxyclozanide was bacteriocidal when tested in vitro against multi-drug-resistant strains of Staphylococcus aureus.…
Many countries have inadequate plans to tackle antibiotic resistance, WHO findsJust a quarter of countries around the world have adequate plans in place to combat resistance to antibiotics, a survey by the World Health Organization has found.…
Hepatitis C drugs hit by incompatibility warnings Gilead’s hepatitis C drugs Harvoni and Sovaldi and Bristol-Myers Squibb’s Daklinza have been hit by warnings from drug regulators regarding their incompatibility with amiodarone.…
Could an Anglo-Saxon remedy help kill MRSA?An Anglo-Saxon recipe that combines garlic, leeks, wine and ox gall may be a useful antibacterial agent, writes Pam Mason.…
Imatinib mimics physiological response to produce antimicrobial effectsThe anti-cancer agent imatinib at very low doses mimics a physiological innate response to infection in the bone marrow, research shows.…
Alternative antibiotic regimens effective for resource-poor settings A major research venture has yielded two antibiotic regimens for treating severe infections that can be administered in the outpatient setting.…
Antibiotic-resistant infections6 April 2015: Sky News reported on a new antibiotic resistant superbug and warned that drug resistant infections will continue to rise without new antibiotics. Speaking to the channel, Royal Pharmaceutical Society (RPS) spokesperson Jayne Lawrence said: “The pharmaceutical industry is not…
Low doses of sequential antibiotics could treat infections, study finds Sequential therapy with two synergistic antibiotics over a period of 96 hours cleared bacterial infection in an in vitro treatment model of Escherichia coli.…